Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Backed by 40-plus years of experience, the new Grandview Max stakes it claim as this spring's open-toed outdoor overlord.

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

Yes, we know, it's still February and yet we can't stop going on about hiking sandals, but what can we say? Our toes are ...

Teva CEO Richard Francis said that he had not expected such a harsh reaction from the market but he sees a positive side to ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...

The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical ...